DA
PMVP icon

Denali Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Denali Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-33,900
Closed -$105K – 490
2023
Q4 		$105K Buy
33,900
+3,400
+11% +$9K 0.03% 268
2023
Q3 		$187K Hold
30,500
– – 0.07% 231
2023
Q2 		$191K Buy
+30,500
New +$160K 0.07% 220

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Denali Advisors's PMVP Position: Q1 2024 in Review

Denali Advisors sold out of PMV Pharmaceuticals (PMVP) in Q1 2024, closing a stake of 33,900 shares — an estimated $105K sold.

Denali Advisors first reported a position in PMVP in Q2 2023 and held it in 3 quarters. The position peaked at $191K in Q2 2023. 99 funds tracked by Wall St. Rank hold PMVP as of Q1 2024.

  • Denali Advisors reported no remaining PMV Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Denali Advisors sold 33,900 PMV Pharmaceuticals shares in Q1 2024, an estimated $105K.
  • Denali Advisors first reported a position in PMV Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Denali Advisors's PMV Pharmaceuticals position peaked at $191K in Q2 2023.
  • 99 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2024.

Based on Denali Advisors's 13F filing for Q1 2024, filed 19 Apr 2024.